LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31)
LIFEVANTAGE CORP (LFVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) of $1.32 million for the 12-month period ending 2012-06-30, per its 10-K filed 2012-09-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost · last filed 2012-09-10
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for fiscal 2012 was $1.32M, a 72.55% increase from fiscal 2011.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for fiscal 2011 was $766.49K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-06-30 | $1.32M 10-K · filed 2012-09-10 |
| 2011-06-30 | $766.49K 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |